Johnson & Johnson's vector vaccine will contribute 18.3 million doses, and a total 70 million doses of vaccines from Sanofi, Novavax and Valneva will contribute the rest.
Australian biotech CSL is already under contract to locally make 50 million doses of the AstraZeneca vaccine, and is currently churning out more than a million doses a week.
Australia is relying on deliveries from Pfizer after restricting the use of AstraZeneca's shot in April in people below 50 years due to rare blood-clotting cases.
This is because available stocks amount to just 529,000 doses of Pfizer's vaccine and 381,000 doses of the AstraZeneca product, an agency official told Reuters.
It added that it had secured a total 192 million doses of vaccines, including those from Moderna Inc, AstraZeneca PLC, Johnson & Johnson's and Novavax.
"The government has acquired COVID-19 vaccines large enough to vaccinate approximately 100 million people...(which) is double the entire population of South Korea," Health Minister Kwon Deok-cheol told a briefing.
There were no cases of severe illness or deaths among those who got the vaccine, the company said.
The vaccine was 86% effective in protecting against the more contagious virus variant first discovered and now prevalent in the United Kingdom, for a combined 90% effectiveness rate overall based on data from infections of both versions of the coronavirus.
That will likely be in the second quarter of 2021, depending on the virulence of the Covid-19 epidemic in the two countries, according to the Novavax statement.
In an analysis of current supply deals for COVID-19 vaccines, the ONE Campaign said wealthy countries, such as the United States and Britain, should share the excess doses to “supercharge” a fully global response to the pandemic.
On Thursday, the World Health Organization urged nations with vaccines not to share them unilaterally, but to donate them to the global COVAX scheme to ensure fairness.
The greenback eased as risk appetite firmed on global vaccination progress, lifting the Malaysian ringgit, Indonesian rupiah and the Thai baht between 0.1% to 0.2%.
Ardern's critics have said New Zealand has fallen behind the rest of the world after promising in November that it would be first in the queue for COVID-19 vaccines.
"NVX-CoV2373 has the potential to play an important role in solving this global public health crisis," said the company's president and CEO Stanley Erck.